Real-world experience of the feasibility and tolerability of the 2:1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Megan Crumbaker; Howard Gurney; Alex Guminski; Shirley Wong; Dhanusha Sabanathan; Nick Pavlakis

Real-world experience of the feasibility and tolerability of the 2:1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Megan Crumbaker, Howard Gurney, Alex Guminski, Shirley Wong, Dhanusha Sabanathan, Nick Pavlakis

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Meeting abstract

Original language	English
Article number	abs#209
Pages (from-to)	47
Number of pages	1
Journal	Asia-Pacific Journal of Clinical Oncology
Volume	12
Issue number	S3
Publication status	Published - Jul 2016
Event	ANZUP Annual Scientific Meeting: Expanding our Horizons - Brisbane, Australia Duration: 10 Jul 2016 → 12 Jul 2016

Cite this

@article{1f4de5060f5d453586181d06468666cd,

title = "Real-world experience of the feasibility and tolerability of the 2:1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia",

author = "Megan Crumbaker and Howard Gurney and Alex Guminski and Shirley Wong and Dhanusha Sabanathan and Nick Pavlakis",

year = "2016",

month = jul,

language = "English",

volume = "12",

pages = "47",

journal = "Asia-Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "Wiley-Blackwell, Wiley",

number = "S3",

note = "ANZUP Annual Scientific Meeting : Expanding our Horizons ; Conference date: 10-07-2016 Through 12-07-2016",

}

Real-world experience of the feasibility and tolerability of the 2:1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia. / Crumbaker, Megan; Gurney, Howard; Guminski, Alex et al.
In: Asia-Pacific Journal of Clinical Oncology, Vol. 12, No. S3, abs#209, 07.2016, p. 47.

Research output: Contribution to journal › Meeting abstract

TY - JOUR

T1 - Real-world experience of the feasibility and tolerability of the 2:1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

AU - Crumbaker, Megan

AU - Gurney, Howard

AU - Guminski, Alex

AU - Wong, Shirley

AU - Sabanathan, Dhanusha

AU - Pavlakis, Nick

PY - 2016/7

Y1 - 2016/7

UR - https://doi.org/10.1111/ajco.12559

M3 - Meeting abstract

C2 - 27406545

SN - 1743-7555

VL - 12

SP - 47

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

IS - S3

M1 - abs#209

T2 - ANZUP Annual Scientific Meeting

Y2 - 10 July 2016 through 12 July 2016

ER -

Real-world experience of the feasibility and tolerability of the 2:1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Other files and links

Cite this